Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 326 of 5804
-
New clamp technique may improve survival in aortic tear surgery
Disease control Recruiting nowThe study is a multicenter, three-arm, open-label, randomized, parallel-controlled trial, which plans to enroll 306 participants diagnosed with acute type A aortic dissection (ATAAD) from 7 hospitals in China. All patients receive total arch replacement (TAR) combined with frozen…
Phase: NA • Sponsor: Beijing Anzhen Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Radioactive implant targets pancreatic tumors from the inside
Disease control Recruiting nowThe goal of this clinical investigation is to learn if a new type of radiotherapy works to treat pancreatic cancer that cannot be removed surgically. It will also learn about the safety of the new treatment when combined with chemotherapy. The treatment involves injecting a radio…
Phase: NA • Sponsor: BetaGlue Therapeutics SpA • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Eye tests may predict Alzheimer's before symptoms show
Diagnosis Recruiting nowAlzheimer's disease (AD) is characterized by a long-lasting silent phase. Among initial events, emergence of tau pathology in locus coeruleus (LC) brainstem nucleus, well before the one observed in medial temporal cortex, is highly relevant. LC integrity and function can be asses…
Phase: PHASE2 • Sponsor: University Hospital, Toulouse • Aim: Diagnosis
Last updated Jul 19, 2026 00:00 UTC
-
New hope for tough prostate cancer: HRS-4357 faces off against standard care in major trial
Disease control Recruiting nowThis study is a randomized, open-label, controlled, multicenter phase III clinical trial, which plans to randomly enroll 370 subjects with advanced metastatic castration-resistant prostate cancer (mCRPC). The efficacy of HRS-4357 versus novel androgen receptor pathway inhibitors …
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
AI-Designed vaccine takes on lung cancer in new trial
Disease control ENROLLING_BY_INVITATIONMicrolyvaq™ is a first-line, non-randomized, two-arm clinical trial in advanced non-small cell lung cancer (NSCLC). In both arms, patients receive a personalized multi-epitope vaccine (Microlyvaq™) on top of standard-of-care chemo-immunotherapy, with treatment tailored by histolo…
Phase: EARLY_PHASE1 • Sponsor: Biogenea Pharmaceuticals Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Blood test boosts liver cancer detection in High-Risk patients
Diagnosis ENROLLING_BY_INVITATIONHCC surveillance is currently limited by underutilization and the suboptimal performance of AFP. This prospective, single-arm study investigates whether the GAAD score (Gender, Age, AFP, and PIVKA-II) enhances HCC detection when added to standard-of-care surveillance. High-risk …
Phase: NA • Sponsor: Siriraj Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
New combo attack on aggressive breast cancer brain tumors shows promise in early trial
Disease control Recruiting nowThis is an open-label, prospective, single-arm, multicenter phase II clinical trial. The aim is to explore the efficacy and safety of radiotherapy combined with cisplatin/carboplatin, adebrelimab, and bevacizumab in patients with triple-negative breast cancer and brain metastases…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail aims to snuff out residual AML before it returns
Disease control Recruiting nowThe purpose of this research study is to test the safety and efficacy of a new drug combination with three agents, azacitidine, venetoclax and tagraxofusp. Leftover (residual) leukemia disease that is not visible by eye can be increase the chance of disease recurrence. This resea…
Phase: PHASE1, PHASE2 • Sponsor: Jacqueline Garcia, MD • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Supercharged immune cells take on kidney cancer in new trial
Disease control Recruiting nowPhase 1/2 study evaluates the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CD70/CAIX CAR-NK cells after fludarabine/cyclophosphamide lymphodepletion in adults with advanced or metastatic clear cell RCC that has progressed after standard therap…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take aim at Hard-to-Treat colorectal cancer
Disease control Recruiting nowThis Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of an allogeneic dual-target chimeric antigen receptor natural killer (CAR-NK) cell product in adults with advanced or metastatic colorectal cancer (CRC). Participants are assigned to one…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New catheter aims to clear stroke clots faster
Disease control Recruiting nowThe purpose of this study is to assess the safety and the effectiveness of the Adaptive Tip Catheter (ATC) used as a first line direct aspiration thrombectomy technique for patients suffering of an acute ischemic stroke.
Phase: NA • Sponsor: Neuravi Limited • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New inhaled drug aims to fight deadly lung scarring
Disease control Recruiting nowRationale: LTI-03 is an experimental medication breathed into the lungs using an inhaler. It is being studied for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is a progressive, fatal lung disease caused by the death of lung cells involved in oxygen uptake and by prog…
Phase: PHASE2 • Sponsor: Rein Therapeutics • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug duo aims to shrink breast tumors before surgery
Disease control Recruiting nowPatients with Stage II-III HER2-positive breast cancer will receive three cycles of treatment with Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab, followed by imaging assessment. If clinical complete response (cCR) or radiological complete response/near radiological complete res…
Phase: PHASE2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Immune cells engineered to attack lung cancer show promise in early trial
Disease control Recruiting nowThis is a two-part, biomarker-guided Phase 1/2 study evaluating the safety, feasibility, and preliminary anti-tumor activity of off-the-shelf dual-target CAR-NK cells in participants with advanced or metastatic NSCLC whose tumors co-express at least two of the following antigens:…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Supercharged immune cells take on pancreatic cancer in new trial
Disease control Recruiting nowThis example study evaluates the safety, tolerability, and preliminary anti-tumor activity of investigational, dual-targeting chimeric antigen receptor natural killer (CAR-NK) cell products for patients with advanced pancreatic ductal adenocarcinoma (PDAC). Participants are assig…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Engineered immune cells take on Hard-to-Treat breast cancers
Disease control Recruiting nowThis study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1, and in some TNBC cases…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Engineered immune cells take on tough lung cancer
Disease control Recruiting nowThis study is an open-label, multi-center, adaptive Phase 1/2 trial evaluating the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CAR-NK cell products in adults with relapsed or refractory small cell lung cancer (SCLC). Three candidate dual-targ…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Engineered immune cells take aim at Hard-to-Treat breast cancers
Disease control Recruiting nowThis study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1,TNBC cases mesothelin),…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Heart valve trial: fix both leaks at once or just one?
Disease control Not yet recruitingThis study aims to investigate the efficacy and safety of combined mitral and tricuspid transcatheter edge-to-edge repair (TEER) versus isolated mitral TEER in the treatment of patients with mitral regurgitation (MR) combined with tricuspid regurgitation (TR). The expected object…
Phase: NA • Sponsor: Nanjing First Hospital, Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for rare liver disease: drug aims to slow damage
Disease control Not yet recruitingLong-Term Study to Evaluate the Safety and Efficacy in Participants with Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes (EPICS-V)
Phase: PHASE3 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC